UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...

Risdiplam in Type 1 Spinal Muscular Atrophy

The New England journal of medicine, 2021-03, Vol.384 (10), p.915-923

2021

Link zum Volltext

Verfügbarkeit prüfen

Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial

Journal of clinical oncology, 2020-11, Vol.38 (31), p.3592-3603

2020

Link zum Volltext

Verfügbarkeit prüfen

Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis

The New England journal of medicine, 2022-01, Vol.386 (4), p.316-326

2022

Link zum Volltext

Verfügbarkeit prüfen

Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis

The New England journal of medicine, 2017-05, Vol.376 (18), p.1723-1736

2017

Link zum Volltext

Verfügbarkeit prüfen

Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study

The lancet oncology, 2020-05, Vol.21 (5), p.671-684

2020

Link zum Volltext

Verfügbarkeit prüfen

Sotorasib for Lung Cancers with KRAS p.G12C Mutation

The New England journal of medicine, 2021-06, Vol.384 (25), p.2371-2381

2021

Link zum Volltext

Verfügbarkeit prüfen

Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial

The lancet oncology, 2019-01, Vol.20 (1), p.43-56

2019

Link zum Volltext

Verfügbarkeit prüfen

Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia

The New England journal of medicine, 2019-08, Vol.381 (5), p.432-443

2019

Link zum Volltext

Verfügbarkeit prüfen

Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations

The New England journal of medicine, 2020-09, Vol.383 (10), p.931-943

2020

Link zum Volltext

Verfügbarkeit prüfen

JAK inhibitors in dermatology: The promise of a new drug class

Journal of the American Academy of Dermatology, 2017-04, Vol.76 (4), p.736-744

2017

Link zum Volltext

Verfügbarkeit prüfen

Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial

British journal of dermatology (1951), 2016-11, Vol.175 (5), p.902-911

2016

Link zum Volltext

Verfügbarkeit prüfen

Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF / FGFR Aberrations: A Phase I Dose-Expansion Study

Cancer discovery, 2022-02, Vol.12 (2), p.402-415

2022

Link zum Volltext

Verfügbarkeit prüfen

Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma

Journal of clinical oncology, 2017-12, Vol.35 (35), p.3898-3905

2017

Link zum Volltext

Verfügbarkeit prüfen

Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma

Blood, 2019-01, Vol.133 (5), p.436-445

2019

Link zum Volltext

Verfügbarkeit prüfen

Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib

Journal of clinical oncology, 2017-09, Vol.35 (26), p.3010-3020

2017

Link zum Volltext

Verfügbarkeit prüfen

Ibrutinib and Venetoclax for First-Line Treatment of CLL

The New England journal of medicine, 2019-05, Vol.380 (22), p.2095-2103

2019

Link zum Volltext

Verfügbarkeit prüfen

Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia

The New England journal of medicine, 2015-12, Vol.373 (25), p.2425-2437

2015

Link zum Volltext

Verfügbarkeit prüfen

New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management

Critical care (London, England), 2017-04, Vol.21 (1), p.89-11, Article 89

2017

Link zum Volltext

Verfügbarkeit prüfen

Combination Therapy in Treatment of Experimental Pulmonary Aspergillosis: In Vitro and In Vivo Correlations of the Concentration- and Dose- Dependent Interactions between Anidulafungin and Voriconazole by Bliss Independence Drug Interaction Analysis

Antimicrobial Agents and Chemotherapy, 2009-06, Vol.53 (6), p.2382-2391

2009

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 6.676

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(6.010)
Mit Volltextzugriff
(5.071)

Publikationsform

Sprache

15 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Humans
(6.156)
Science & Technology
(5.533)
Life Sciences & Biomedicine
(5.444)
Pyrimidines - Adverse Effects
(4.351)
Male
(3.594)
Female
(3.206)
Pyrimidines - Therapeutic Use
(2.865)
Middle Aged
(2.756)
Adult
(2.319)
Aged
(2.067)
Pyrimidines - Administration & Dosage
(1.810)
Oncology
(1.601)
Biological And Medical Sciences
(1.501)
Medical Sciences
(1.422)
Treatment Outcome
(1.409)
Imatinib Mesylate
(1.392)
Antineoplastic Agents - Adverse Effects
(1.347)
Piperazines - Adverse Effects
(1.267)
Pharmacology & Pharmacy
(1.179)
Benzamides
(1.165)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

Journals@Ovid Complete
(3.046)
Electronic Journals Library - Freely accessible e-journals
(2.703)
IngentaConnect Journals
(2.491)
Single Journals
(1.645)
IngentaConnect Journals
(1.317)
Wiley Online Library Journals Frontfile Complete
(1.110)
Elsevier ScienceDirect Journals Complete
(1.038)
Wiley Online Library Full Collection 2018
(907)
SpringerLink
(765)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(679)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(499)
Taylor & Francis:Master (3349 titles)
(324)
Oxford Journals
(264)
Nexis Uni
(239)
Nature
(239)
Oxford Journals 2020 Medicine
(208)
SAGE Complete
(153)
JSTOR
(111)
BMJ Journals
(107)
SpringerLink Series
(94)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Blood
(117)
Journal Of Clinical Oncology
(102)
The New England Journal Of Medicine
(99)
Leukemia & Lymphoma
(93)
Clinical Cancer Research
(87)
Cancer
(72)
Leukemia Research
(72)
British Journal Of Haematology
(70)
Haematologica
(69)
American Journal Of Hematology
(68)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(37)
... seit 30 Tagen
(7)

Menü

Weitere Dienste

Einstellungen

Risdiplam in Type 1 Spinal Muscular Atrophy

Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial

Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma

Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis

Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis

Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study

Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study

Sotorasib for Lung Cancers with KRAS p.G12C Mutation

Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial

Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia

Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations

Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial

JAK inhibitors in dermatology: The promise of a new drug class

Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial

Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF / FGFR Aberrations: A Phase I Dose-Expansion Study

Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study

Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma

Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma

Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma

Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib

Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH

Ibrutinib and Venetoclax for First-Line Treatment of CLL

Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia

New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management

Combination Therapy in Treatment of Experimental Pulmonary Aspergillosis: In Vitro and In Vivo Correlations of the Concentration- and Dose- Dependent Interactions between Anidulafungin and Voriconazole by Bliss Independence Drug Interaction Analysis

Suchergebnisse filtern